News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Home
| Partnering |
Why partner with usFor biotechnology and pharmaceutical partners, for academic and research organisations we offer flexible deal terms to:
In addition to this, we validate your technology to further attract commercial partners and by financing early-stage projects through equity participation or acquisitions. We can also mitigate the risk and help you relieve your human and financial resources. Particularly for academic and research organisations, our commercial orientated development is an advantage.
For licensing contacts, please use this form.
|



